Publications by authors named "Ruhi Polara"
CD47 is a ubiquitously expressed cell surface receptor, which is widely known for preventing macrophage-mediated phagocytosis by interacting with signal regulatory protein α (SIRPα) on the surface of macrophages. In addition to its role in phagocytosis, emerging studies have reported numerous noncanonical functions of CD47 that include regulation of various cellular processes such as proliferation, migration, apoptosis, differentiation, stress responses, and metabolism. Despite lacking an extensive cytoplasmic signaling domain, CD47 binds to several cytoplasmic proteins, particularly upon engaging with its secreted matricellular ligand, thrombospondin 1.
View Article and Find Full Text PDFArticle Synopsis
- CAR-T cells targeting fibroblast activation protein (FAP) show promise as a new immunotherapy for glioblastoma, with potential against both tumor cells and their blood vessels.
- The study developed and tested a novel FAP-targeting CAR-T cell that demonstrated effective toxicity and immune response, even against glioma stem cells that do not express FAP.
- Results indicate that these CAR-T cells could selectively kill tumor cells while also aiding in the destruction of surrounding, FAP-negative tumor cells through a mechanism enhanced by IL-2, suggesting a potential for greater therapeutic impact without significant side effects.
TFEB is a master regulator of autophagy, lysosome biogenesis, mitochondrial metabolism, and immunity that works primarily through transcription controlled by cytosol-to-nuclear translocation. Emerging data indicate additional regulatory interactions at the surface of organelles such as lysosomes. Here we show that TFEB has a non-transcriptional role in mitochondria, regulating the electron transport chain complex I to down-modulate inflammation.
View Article and Find Full Text PDFAdjuvant chemotherapy is highly recommended for liver cancer to enhance survival rates due to its tendency to recur frequently. Localized drug-eluting implants have gained traction as an alternative to overcome the limitations of systemic chemotherapy. This work describes the development of biodegradable 3D printed (3DP) bilayer films loaded with 5-fluorouracil (5FU) and cisplatin (Cis) with different infill percentages where the 5FU layers were 40%, 30%, and 30% and Cis layers were 10%, 15%, and 10% for films A, B, and C, respectively.
View Article and Find Full Text PDFArticle Synopsis
- Vitamin D regulation in humans primarily relies on the enzyme CYP24A1, which hydroxylates key vitamin D metabolites, and its upregulation is linked to diseases like chronic kidney disease (CKD).
- Increased CYP24A1 activity in CKD leads to reduced vitamin D effectiveness, contributing to issues like secondary hyperparathyroidism and bone loss.
- Researchers developed a new vitamin D analogue that inhibits CYP24A1, showing promise in enhancing vitamin D activity and potentially offering a new treatment approach for secondary hyperparathyroidism.